Continuation Versus Discontinuation of Buprenorphine in the Perioperative Setting: A Retrospective Study.
anesthesia
buprenorphine
chronic pain
naloxone
perioperative
postoperative pain
suboxone
subutex
surgery
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
accepted:
22
03
2022
entrez:
28
4
2022
pubmed:
29
4
2022
medline:
29
4
2022
Statut:
epublish
Résumé
Background Buprenorphine use continues to grow for the management of opioid use disorder (OUD) and chronic pain management. In the face of this increase in use, perioperative buprenorphine management continues to have conflicting recommendations with no consensus on optimal management. We examined the effects of holding versus continuing perioperative buprenorphine in patients on chronic buprenorphine therapy to seek an answer to whether it should be continued or discontinued in the perioperative period. Methods Patients who were included in the study had surgery from 2011 to 2020 and had received buprenorphine within 30 days prior to their surgery, were admitted postoperatively for at least 48 hours, went to the postanesthesia care unit (PACU) immediately after surgery, and were successfully extubated. For these 275 patients, the included factors were age, gender, primary surgical service, anesthesia type, postoperative opioid use, preoperative regional block performed, and inpatient pain service (IPS) consultation. The analysis included differences between patients who had continued versus discontinued buprenorphine either preoperatively or postoperatively. Results A total of 275 patients were treated within 30 days of surgery with buprenorphine; of these, 147 (53.4%) patients continued buprenorphine, and 128 (46.6%) discontinued buprenorphine preoperatively. For patients who discontinued buprenorphine preoperatively, the mean days stopped before surgery was 3.5 days. Patients continuing buprenorphine preoperatively had a significantly lower postoperative opioid requirement. In addition, patients were significantly younger and more likely to be female and had fewer IPS consultations than those who discontinued buprenorphine. Buprenorphine was restarted postoperatively for 143 (52%) patients and held for 132 (48%) postoperatively. Conclusions The use of buprenorphine perioperatively was associated with significantly reduced oral morphine equivalent (OME) requirements postoperatively. Further research is needed to give definitive recommendations for whether to continue or discontinue buprenorphine prior to surgery.
Identifiants
pubmed: 35481308
doi: 10.7759/cureus.23385
pmc: PMC9033510
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e23385Informations de copyright
Copyright © 2022, Schuster et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Neuropsychopharmacology. 2003 Nov;28(11):2000-9
pubmed: 12902992
Anesthesiology. 2017 Jun;126(6):1180-1186
pubmed: 28511196
Ann N Y Acad Sci. 2012 Feb;1248:124-39
pubmed: 22256949
Curr Pain Headache Rep. 2016 Mar;20(3):16
pubmed: 26879874
Pain Med. 2019 Jul 1;20(7):1395-1408
pubmed: 30500943
BMC Anesthesiol. 2019 May 8;19(1):68
pubmed: 31068127
Pain Physician. 2018 Jan;21(1):E1-E12
pubmed: 29357325
Addiction. 2009 Feb;104(2):256-65
pubmed: 19149822
Pain Med. 2019 Mar 1;20(3):425-428
pubmed: 29452378
Br J Anaesth. 2019 Aug;123(2):e333-e342
pubmed: 31153631
J Arthroplasty. 2016 Aug;31(8):1698-701
pubmed: 26899477
J Pain. 2016 Feb;17(2):131-57
pubmed: 26827847